Neumora Therapeutics, Inc. to Post FY2028 Earnings of $0.35 Per Share, William Blair Forecasts (NASDAQ:NMRA)

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Investment analysts at William Blair issued their FY2028 earnings estimates for Neumora Therapeutics in a research note issued on Tuesday, August 6th. William Blair analyst M. Minter anticipates that the company will post earnings per share of $0.35 for the year. William Blair has a “Outperform” rating on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.46) per share.

Several other equities analysts have also recently weighed in on NMRA. Needham & Company LLC reissued a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a research note on Wednesday. Mizuho began coverage on shares of Neumora Therapeutics in a research note on Monday, July 8th. They issued an “outperform” rating and a $20.00 price target for the company. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $22.33.

Neumora Therapeutics Stock Performance

NMRA stock opened at $11.24 on Wednesday. Neumora Therapeutics has a twelve month low of $8.33 and a twelve month high of $21.00. The business has a 50 day moving average price of $10.67 and a two-hundred day moving average price of $12.66.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37).

Hedge Funds Weigh In On Neumora Therapeutics

Large investors have recently modified their holdings of the stock. Amalgamated Bank acquired a new stake in Neumora Therapeutics during the 4th quarter worth approximately $29,000. Tower Research Capital LLC TRC acquired a new stake in shares of Neumora Therapeutics during the fourth quarter worth $44,000. Strs Ohio bought a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $54,000. SG Americas Securities LLC acquired a new position in shares of Neumora Therapeutics in the fourth quarter valued at about $108,000. Finally, New York State Common Retirement Fund bought a new position in Neumora Therapeutics during the fourth quarter worth about $118,000. 47.65% of the stock is owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.